Clinical Trial

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. BMS986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab with BMS986205 may work better than nivolumab alone in treating patients with squamous cell cancer of the head and neck.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2019-02-21; most recent amendment 2026-05-15.
Status change: Active, Not Recruiting → Completed 2026-03-10
Status change: Terminated → Active, Not Recruiting 2025-02-03
Status change: Active, Not Recruiting → Terminated 2024-07-25
Status change: Recruiting → Active, Not Recruiting 2022-11-16
Status change: Not Yet Recruiting → Recruiting 2019-04-11
Trial Details
NCT Number NCT03854032
Lead Sponsor Thomas Jefferson University
Collaborators: Bristol-Myers Squibb
Conditions Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
Enrollment 45 participants
Start Date 2019-04-09
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-06